TOKYO, April 23, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 679 million (USD 4.5 million1) for the development of diagnostics for tuberculosis, in addition to an investment of approximately JPY 15.9 million (USD 0.1 million1) for a drug discovery project for Chagas disease and leishmaniasis.2
Investment of approximately JPY 679 million (USD 4.5 million1) for the development of diagnostics for tuberculosis
Tuberculosis (TB) remains a serious infectious disease, with approximately 10.8 million cases and 1.25 million deaths reported in 2023, making it the leading causes of death from a single infectious agent.3 The United Nations' Sustainable Development Goals (SDGs) set a target to end TB by 2030, but achieving this goal requires accurate and accessible diagnostic technologies. Current TB tests face challenges such as low sensitivity, high costs, complexity, and the need for specialized equipment and sputum samples, making them unsuitable for all patients. In particular, children, people with conditions who cannot produce sputum, and those in resource-limited settings often struggle to receive timely diagnoses, causing the continued spread of the disease. To address this issue, the GHIT Fund has decided to invest approximately JPY 679 million (USD 4.5 million1) towards a new TB diagnostic development project by US-based diagnostic developer Fluxus, Inc., 4 in partnership with Fujirebio, Inc., a developer of clinical diagnostics in Japan,4 and Heidelberg University Hospital in Germany.
This project will leverage Fluxus' cutting-edge ultrasensitive detection technology to develop and validate a urine-based TB biomarker lipoarabinomannan (LAM) assay on its automated benchtop immunoassay analyzer. Additionally, the project will design and develop critical components for a portable, ultrasensitive point-of-care (PoC) system that integrates the urine LAM test. This advanced technology will enable rapid, accurate, and accessible diagnosis across a broader patient population, contributing to improved clinical outcomes and reduced transmission.
In addition, the GHIT Fund will invest approximately JPY 15.9 million (USD 0.1 million1) in a screening project against Chagas disease and leishmaniasis by Kitasato University, Nagasaki University, University of Tokyo, and Drugs for Neglected Diseases initiative (DNDi).
Please refer to Appendix 1 for detailed descriptions on these projects and their development stages.
As of March 31, 2025, the GHIT Fund has invested in 36 projects, including 15 discovery projects, 12 preclinical projects, and 9 clinical trials.5 The total amount of investments since 2013 is JPY 38.2 billion (USD 255 million1) (Appendix 2).
1 USD1 = JPY149.53, the approximate exchange rate on March 31, 2025.
2 These awarded projects were selected and approved as new investments from among proposals to RFP2023-002 and RFP2024-001 for the Product Development Platform and the Screening Platform, which were open for applications from June 2023 to July 2024.
3 WHO: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
4 Fluxus, Inc. and Fujirebio, Inc. are members of Fujirebio.
5 This number includes projects in the registration phase.
The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world's vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https://www.ghitfund.org/en
Appendix 1. Project Details
ID: G2023-204
Project Title | Ultrasensitive Detection of Urine LAM for Point-of-Care Rapid Diagnosis of All Forms |
Collaboration Partners | 1. Fluxus, Inc. (USA) 2. Fujirebio, Inc. (Japan) 3. Heidelberg University Hospital (Germany) |
Disease | Tuberculosis |
Intervention | Diagnostics |
Stage | Product Design, Product development |
Awarded Amount | JPY 679,783,110 (USD 4.54 million) |
Status | New project |
Summary | [Project objective] To develop a prototype portable point-of-care (PoC) system and integrated ultrasensitive
[Project design] |
Project Detail | https://www.ghitfund.org/investment/portfoliodetail/detail/240/en |
ID: S2024-122
Project Title | Searching for Chagas disease therapeutic seed compounds from microbial cultures |
Collaboration Partners | 1. Kitasato University (Japan) 2. Nagasaki University (Japan) 3. University of Tokyo (Japan) 4. Drugs for Neglected Diseases initiative (DNDi) (Switzerland) |
Disease | Chagas disease / Leishmaniasis |
Intervention | Drug |
Stage | Screening |
Awarded Amount | JPY 15,945,864 (USD 106,639) |
Status | New project |
Summary | [Project objective] The main objective of our proposed project is to identify novel T. cruzi active scaffolds
[Project design] |
Project Detail | https://www.ghitfund.org/investment/portfoliodetail/detail/241/en |
*All amounts are listed at an exchange rate of USD1 = JPY149.53, the approximate exchange rate on March 31, 2025.
Appendix 2. Investment Overview (as of March 31, 2025)
Investments to date
Total investments: 38.2 billion yen (USD 255 million1)
Total invested projects: 136 (36 active projects and 100 completed projects)
To learn more about the GHIT Fund's investments, please visit
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en
For more information, contact:
Katy Lenard at +1-301-280-5719 or [email protected]
Mina Ohata at +81-36441-2032 or [email protected]
